MED18

Across TCGA pan-cancer cohorts, MED18 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED18 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MED18 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED18 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where MED18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.673	0.903	<.001	45	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.476	<.001	33	view →
HNSC	DFS	Median	IV	0.889	0.407	.042	2	view →
CCRCC	OS	Quartile	III,IV	1.000	0.742	.044	1	view →
GBM	OS	Tertile	All	0.487	0.290	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MED18–PDAC (DFS)

Open the PDAC breakdown →